Comparative effectiveness of spironolactone versus oral tetracycline-class antibiotics for the treatment of moderate to severe acne in women
Comparative effectiveness of spironolactone versus oral tetracycline-class antibiotics for the treatment of moderate to severe acne in women
批准号:
9815052
负责人:
David Margolis
金额:
$24.95万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-01 至 2021-06-30
关键词:
AcneAdolescentAdultAffectAntibiotic ResistanceAntibiotic TherapyAntibioticsAreaAttentionBacterial Antibiotic ResistanceBlood VesselsBudgetsCaringCellulitisCenters for Disease Control and Prevention (U.S.)ClinicalClinical trial protocol documentCollagenColon CarcinomaDataData Coordinating CenterDermatologistDevelopmentDiseaseDiureticsEffectivenessEnrollmentExpert OpinionExposure toFeelingGoalsGuidelinesHealthcareHormonalInflammatory Bowel DiseasesInfrastructureInstitute of Medicine (U.S.)Institutional Review BoardsInternationalInvestigational DrugsIsotretinoinManualsMedicineMinorityMonitorOralOutpatientsPathogenesisPatientsPharmaceutical PreparationsPharyngitisPoliciesPotassiumPreparationProceduresProcessProtocols documentationProviderPsoriasisRandomized Clinical TrialsResearch DesignResearch PersonnelRetrospective StudiesSample SizeSiteSpironolactoneStatistical Data InterpretationTetracyclinesTimeLineUnited States National Institutes of HealthWomanWorkadverse outcomebacterial resistanceburden of illnessclinical research sitecomparative effectivenesscompare effectivenessdesigneffectiveness researchhormone therapyimprovedinformatics infrastructureinterestmalignant breast neoplasmmedical specialtiesmeetingsmelanomamicrobiomenoveloff-label usepatient populationprospectiverecruitsuccesstherapy durationtrial comparing
中文摘要
项目总结/摘要
痤疮是世界范围内最常见的疾病之一,影响85%的青少年,并且经常持续存在
长大成人痤疮是负责一个更大的全球疾病负担比牛皮癣,蜂窝织炎,
黑素瘤虽然轻度痤疮通常可以用局部药物治疗,但中度至重度痤疮通常
需要用全身性药物如口服抗生素、激素疗法和异维甲酸治疗。
值得注意的是,虽然这些药物是护理的标准部分,但很少有随机临床试验
这些常用药物之间显示出有效性,而没有显示出比较有效性;
医学研究所已将这一领域确定为比较有效性研究的首要任务之一。
我们小组以前的工作表明,口服抗生素是最常见的全身性药物,
治疗痤疮和患者经常使用它们超过一年。事实上,皮肤科医生会开
人均抗生素比其他任何专科都多。然而,长期使用抗生素可能与
各种不良后果,包括细菌抗生素耐药性,咽炎,胶原血管疾病,
炎症性肠病以及乳腺癌和结肠癌。因此,国际社会对
疾病控制中心特别关注改善抗生素管理,
门诊设置和痤疮的多个临床指南建议减少使用
通过使用非抗菌治疗和限制治疗持续时间来减少抗生素。
对于中度至重度痤疮的女性,螺内酯可能是一种有效的,耐受性良好的药物,
替代口服抗生素。作为一种保钾利尿剂开发,多年来它也被用于
由于其对这种疾病的激素发病机制的影响,尽管专家认为
支持使用螺内酯治疗痤疮,其使用仍然相对罕见和临床
证明螺内酯有效性的证据仅限于小型的、通常是回顾性的研究。
缺乏将螺内酯与其他药物(如口服抗生素)的有效性进行比较的试验。
我们的最终目标是完成必要的规划和准备,进行一个新颖的,前瞻性的,
评价螺内酯和口服四环素类药物疗效的随机临床试验
痤疮的治疗方法有哪些?以前没有进行过这样的研究。结果
这项研究的结果将对痤疮的治疗和抗生素管理产生重大影响。在
此外,这项研究可能使我们能够监测抗生素耐药性发展的时间,
接受延长抗生素疗程治疗的健康患者人群,并评估
长期暴露于口服抗生素对微生物组的影响。我们提出的研究可能会显著影响
关于治疗女性中度至重度痤疮的医疗实践和知情政策
关于在整个医疗过程中更恰当地使用抗生素的建议。
英文摘要
Project Summary/Abstract
Acne is one of the most common diseases worldwide, affecting 85% of adolescents and often persisting
into adulthood. Acne is responsible for a greater global burden of disease than psoriasis, cellulitis, and
melanoma. While mild acne can usually be managed with topical medications, moderate to severe acne often
requires treatment with systemic agents such as oral antibiotics, hormonal therapies, and isotretinoin.
Remarkably, while these agents are a standard part of care, there are very few randomized clinical trials
showing efficacy and none that show comparative effectiveness between these commonly used agents; the
Institute of Medicine has identified this area as one of the top priorities for comparative effectiveness research.
Previous work by our group has shown oral antibiotics are the most common systemic agent used in the
treatment of acne and patients frequently use them for more than one year. In fact, dermatologists prescribe
more antibiotics per capita than any other specialty. However, prolonged antibiotic use may be associated with
a variety of adverse outcomes including bacterial antibiotic resistance, pharyngitis, collagen vascular illnesses,
inflammatory bowel disease, and breast and colon cancer. As a result, there is growing international interest
and attention specifically from the Centers for Disease Control regarding improving antibiotic stewardship in
the outpatient setting and multiple clinical guidelines for acne have recommended reducing the use of
antibiotics through the use of non-antimicrobial therapies and by limiting the duration of therapy.
For women with moderate to severe acne, spironolactone may represent an effective, well-tolerated
alternative to oral antibiotics. Developed as a potassium-sparing diuretic, for many years it has also been used
off-label for acne due to its impact on hormonal pathogenesis of this disease. However, despite expert opinion
supporting the use of spironolactone in the treatment of acne, its use remains relatively uncommon and clinical
evidence demonstrating the effectiveness of spironolactone is limited to small, often retrospective studies.
Trials comparing the effectiveness of spironolactone to that of other agents such as oral antibiotics are lacking.
Our ultimate goal is to complete the necessary planning and preparation to conduct a novel, prospective,
randomized clinical trial evaluating the comparative effectiveness of spironolactone and oral tetracycline-class
antibiotics in the treatment of acne in adult women. No such study has previously been conducted. The results
of this study would have substantial implications for the treatment of acne and antibiotic stewardship. In
addition, this study may allow us to monitor for the timing of the development of antibiotic resistance in a
healthy population of patients treated with extended courses of antibiotics and to evaluate the impact of
prolonged exposure to oral antibiotics on the microbiome. Our proposed study could significantly influence
healthcare practice with respect to the treatment of moderate to severe acne in women and inform policy
regarding more appropriate use of antibiotics throughout medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women
-
批准号:10296086
-
项目类别:
-
资助金额:$104.05万
-
财政年份:2021
-
负责人:David Margolis
-
依托单位:
A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women
-
批准号:10470869
-
项目类别:
-
资助金额:$102.93万
-
财政年份:2021
-
负责人:David Margolis
-
依托单位:
NOS1AP and Capon Associated Impaired Healing in Those with Diabetic Foot Ulcers
-
批准号:9925084
-
项目类别:
-
资助金额:$60.51万
-
财政年份:2018
-
负责人:David Margolis
-
依托单位:
African-Americans with Atopic Dermatitis: Skin Barrier and Immune
-
批准号:9228322
-
项目类别:
-
资助金额:$55.13万
-
财政年份:2016
-
负责人:David Margolis
-
依托单位:
Data Sciences and Informatics
-
批准号:10477235
-
项目类别:
-
资助金额:$23.37万
-
财政年份:2016
-
负责人:David Margolis
-
依托单位:
African-Americans with Atopic Dermatitis: Skin Barrier and Immune
-
批准号:9868281
-
项目类别:
-
资助金额:$34.43万
-
财政年份:2016
-
负责人:David Margolis
-
依托单位:
Data Sciences and Informatics
-
批准号:10663986
-
项目类别:
-
资助金额:$23.37万
-
财政年份:2016
-
负责人:David Margolis
-
依托单位:
Stem cell mobilization and diabetic skin ulcers
-
批准号:8538377
-
项目类别:
-
资助金额:$58.57万
-
财政年份:2012
-
负责人:David Margolis
-
依托单位:
Stem cell mobilization and diabetic skin ulcers
-
批准号:8370929
-
项目类别:
-
资助金额:$76.73万
-
财政年份:2012
-
负责人:David Margolis
-
依托单位:
Stem cell mobilization and diabetic skin ulcers
-
批准号:8731122
-
项目类别:
-
资助金额:$59.42万
-
财政年份:2012
-
负责人:David Margolis
-
依托单位:
Stem cell mobilization and diabetic skin ulcers
-
批准号:9122402
-
项目类别:
-
资助金额:$14.71万
-
财政年份:2012
-
负责人:David Margolis
-
依托单位:
Comparative Effectiveness of Adjunctive Devices For the Previous
-
批准号:8230818
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2011
-
负责人:David Margolis
-
依托单位:
Comparative Effectiveness of Adjunctive Devices For the Previous
-
批准号:8108418
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:David Margolis
-
依托单位:
Comparative Effectiveness of Adjunctive Devices For the Previous
-
批准号:8447992
-
项目类别:
-
资助金额:$27.46万
-
财政年份:2011
-
负责人:David Margolis
-
依托单位:
Filaggrin Mutations and the Prognosis of Atopic Dermatitis
-
批准号:8321208
-
项目类别:
-
资助金额:$5.43万
-
财政年份:2009
-
负责人:David Margolis
-
依托单位:
Filaggrin Mutations and the Prognosis of Atopic Dermatitis
-
批准号:7808038
-
项目类别:
-
资助金额:$54.74万
-
财政年份:2009
-
负责人:David Margolis
-
依托单位:
Filaggrin Mutations and the Prognosis of Atopic Dermatitis
-
批准号:8040004
-
项目类别:
-
资助金额:$50.71万
-
财政年份:2009
-
负责人:David Margolis
-
依托单位:
Filaggrin Mutations and the Prognosis of Atopic Dermatitis
-
批准号:8242639
-
项目类别:
-
资助金额:$29.75万
-
财政年份:2009
-
负责人:David Margolis
-
依托单位:
Filaggrin Mutations and the Prognosis of Atopic Dermatitis
-
批准号:7565094
-
项目类别:
-
资助金额:$54.81万
-
财政年份:2009
-
负责人:David Margolis
-
依托单位:
Acne and group A strep: an unknown burden
-
批准号:6864401
-
项目类别:
-
资助金额:$58.0万
-
财政年份:2005
-
负责人:David Margolis
-
依托单位:
海外基金